ABBV · 10-Q · 2026Q3 · Full report
U.S. Manufacturing Investment
AbbVie Inc. · 2026-11-03 · Importance 40 · Surprise 42 · In source text
In 2026, AbbVie announced an investment to build a pharmaceutical manufacturing campus in North Carolina, integrating advanced manufacturing and laboratory technologies with artificial intelligence. The campus is intended to support production of immunology, neuroscience and oncology medicines. AbbVie also announced investments in two new Illinois manufacturing facilities for next-generation neuroscience and obesity medications, and an agreement to acquire an Arizona device manufacturing facility that closed in July 2026. The projects are part of the company’s plan to invest in the U.S. to support innovation and expand manufacturing capabilities and capacity; the filing does not specify investment amounts for these projects.
Key facts
- AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. source
- In 2026, AbbVie announced an investment to build a pharmaceutical manufacturing campus in North Carolina integrating advanced manufacturing and laboratory technologies with artificial intelligence to support production of immunology, neuroscience, and oncology medicines. source
- AbbVie announced investments in two new Illinois manufacturing facilities for next-generation neuroscience and obesity medications and an agreement to acquire an Arizona device manufacturing facility, which closed in July 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -57.5% | AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. |